€45.20
0.24%
Xetra, Nov 17, 05:35 pm CET. Closed.
ISIN
NL0000240000
Symbol
QIA

Qiagen Target price 2026 - Analyst rating & recommendation

Qiagen Classifications & Recommendation

Buy
38%
Hold
62%

Qiagen Price Target

Target Price €46.77
Price €45.20
Potential 3.47%
Number of Estimates 16
16 Analysts have issued a price target Qiagen 2027 . The average Qiagen target price is €46.77. This is 3.47% higher than the current stock price. The highest price target is €50.54 11.81% , the lowest is €36.69 18.83% .
A rating was issued by 21 analysts: 8 Analysts recommend Qiagen to buy, 13 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Qiagen stock has an average upside potential 2027 of 3.47% . Most analysts recommend the Qiagen stock at Hold.

Sales and Margin forecast 2026, 2027 to 2030

Sign up for free to unlock analyst estimates. Sign up for free

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Revenue Billion € ??? ???
??? ???
EBITDA Margin ??? ???
??? ???
Net Margin ??? ???
??? ???

23 Analysts have issued a sales forecast Qiagen 2026 . The average Qiagen sales estimate is

. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .

This results in the following potential growth metrics:

Revenue Estimates

2025 €1.9b 5.65%
2026
2027
2028
2029
2030

21 Analysts have issued an Qiagen EBITDA forecast 2026. The average Qiagen EBITDA estimate is

. This is than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is , the lowest is .

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 €508m 10.88%
2026
2027
2028
2029
2030

EBITDA Margin

2025 26.77% 4.95%
2026
2027
2028
2029
2030

23 Qiagen Analysts have issued a net profit forecast 2026. The average Qiagen net profit estimate is

. This is than the net profit for the last 12 months(TTM). The highest net profit forecast is , the lowest is .

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 €386m 408.30%
2026
2027
2028
2029
2030
2031

Net Margin

2025 20.33% 381.11%
2026
2027
2028
2029
2030

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2031

Sign up for free to unlock analyst estimates. Sign up for free

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Earnings Per Share € ??? ???
??? ???
P/E ???
EV/Sales ???

23 Analysts have issued a Qiagen forecast for earnings per share. The average Qiagen EPS is

. This is than earnings per share in the financial year 2025. The highest EPS forecast is , the lowest is .

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 €1.77 378.38%
2026
2027
2028
2029
2030
2031

P/E ratio

Current 25.46 5.38%
2026
2027
2028
2029
2030
2031

Based on analysts' sales estimates for 2026, the Qiagen stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 5.30 9.28%
2026
2027
2028
2029
2030

P/S ratio

Current 4.90 5.52%
2026
2027
2028
2029
2030

Current Qiagen Upgrades & Downgrades

Analyst Rating Action Date
UBS
Neutral
➜
Neutral
Unchanged Nov 13 2026
Barclays
Overweight
➜
Equal-Weight
Downgrade Oct 28 2026
Citigroup
Neutral
➜
Neutral
Unchanged Oct 26 2026
Baird
Outperform
➜
Outperform
Unchanged Oct 22 2026
JP Morgan
Overweight
➜
Neutral
Downgrade Oct 22 2026
JP Morgan
Overweight
➜
Overweight
Unchanged Oct 14 2026
Barclays
Equal-Weight
➜
Overweight
Upgrade Oct 06 2026
Analyst Rating Date
Unchanged
UBS:
Neutral
➜
Neutral
Nov 13 2026
Downgrade
Barclays:
Overweight
➜
Equal-Weight
Oct 28 2026
Unchanged
Citigroup:
Neutral
➜
Neutral
Oct 26 2026
Unchanged
Baird:
Outperform
➜
Outperform
Oct 22 2026
Downgrade
JP Morgan:
Overweight
➜
Neutral
Oct 22 2026
Unchanged
JP Morgan:
Overweight
➜
Overweight
Oct 14 2026
Upgrade
Barclays:
Equal-Weight
➜
Overweight
Oct 06 2026

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today